Healios K.K. (4593.T)
- Previous Close
154.00 - Open
149.00 - Bid 148.00 x --
- Ask 149.00 x --
- Day's Range
147.00 - 154.00 - 52 Week Range
114.00 - 332.00 - Volume
686,600 - Avg. Volume
1,410,708 - Market Cap (intraday)
13.339B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-56.23 - Earnings Date Aug 13, 2024 - Aug 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
302.50
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
www.healios.co.jpRecent News: 4593.T
Performance Overview: 4593.T
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4593.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4593.T
Valuation Measures
Market Cap
13.88B
Enterprise Value
11.69B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
86.55
Price/Book (mrq)
3.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.00%
Return on Equity (ttm)
-92.44%
Revenue (ttm)
121M
Net Income Avi to Common (ttm)
-3.82B
Diluted EPS (ttm)
-56.23
Balance Sheet and Cash Flow
Total Cash (mrq)
6.72B
Total Debt/Equity (mrq)
117.17%
Levered Free Cash Flow (ttm)
-1.42B
Research Analysis: 4593.T
Company Insights: 4593.T
4593.T does not have Company Insights